Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept

Marieke H. Otten; Femke H. M. Prince; Marinka Twilt; Marion A. J. van Rossum; Wineke Armbrust; Esther P. A. H. Hoppenreijs; Sylvia Kamphuis; Yvonne Koopman-Keemink; Nico M. Wulffraat; Simone L. Gorter; Rebecca ten Cate; Lisette W. A. van Suijlekom-Smit

doi:10.3899/jrheum.090550

Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept

Marieke H. Otten^*, Femke H. M. Prince, Marinka Twilt, Marion A. J. van Rossum, Wineke Armbrust, Esther P. A. H. Hoppenreijs, Sylvia Kamphuis, Yvonne Koopman-Keemink, Nico M. Wulffraat, Simone L. Gorter, Rebecca ten Cate, Lisette W. A. van Suijlekom-Smit

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Objective. To evaluate response in patients with juvenile idiopathic arthritis (JIA) who failed to meet response criteria after 3 months of etanercept treatment. Methods. This was a prospective ongoing Multicenter observational study of all Dutch patients with JIA using etanercept. Response according to American College of Rheumatology Pediatric 30 criteria was assessed at study start and at 3 and 15 months. Results. In total we studied 179 patients of median age 5.8 years at disease onset; 70% were female. Thirty-four patients did not respond after 3 months, of which 20 continued etanercept and 11 achieved response thereafter. Conclusion. The delayed clinically relevant response in a substantial proportion of patients who initially did not respond justifies the consideration of continuing therapy to at least 6 months. (First Release Jan 15 2010; J Rheumatol 20 10;37:665-7 doi: 10.3899/jrheum.090550)

Original language	English
Pages (from-to)	665-667
Journal	Journal of Rheumatology
Volume	37
Issue number	3
DOIs	https://doi.org/10.3899/jrheum.090550
Publication status	Published - Mar 2010

Keywords

JUVENILE IDIOPATHIC ARTHRITIS
ANTIRHEUMATIC AGENTS
TUMOR NECROSIS FACTOR-alpha
DRUG ADMINISTRATION SCHEDULE
TREATMENT OUTCOME
ARTHRITIS

Access to Document

10.3899/jrheum.090550

Cite this

Otten, M. H., Prince, F. H. M., Twilt, M., van Rossum, M. A. J., Armbrust, W., Hoppenreijs, E. P. A. H., Kamphuis, S., Koopman-Keemink, Y., Wulffraat, N. M., Gorter, S. L., ten Cate, R., & van Suijlekom-Smit, L. W. A. (2010). Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept. Journal of Rheumatology, 37(3), 665-667. https://doi.org/10.3899/jrheum.090550

@article{9a8095c701174c98a4a3151027380215,

title = "Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept",

abstract = "Objective. To evaluate response in patients with juvenile idiopathic arthritis (JIA) who failed to meet response criteria after 3 months of etanercept treatment. Methods. This was a prospective ongoing Multicenter observational study of all Dutch patients with JIA using etanercept. Response according to American College of Rheumatology Pediatric 30 criteria was assessed at study start and at 3 and 15 months. Results. In total we studied 179 patients of median age 5.8 years at disease onset; 70% were female. Thirty-four patients did not respond after 3 months, of which 20 continued etanercept and 11 achieved response thereafter. Conclusion. The delayed clinically relevant response in a substantial proportion of patients who initially did not respond justifies the consideration of continuing therapy to at least 6 months. (First Release Jan 15 2010; J Rheumatol 20 10;37:665-7 doi: 10.3899/jrheum.090550)",

keywords = "JUVENILE IDIOPATHIC ARTHRITIS, ANTIRHEUMATIC AGENTS, TUMOR NECROSIS FACTOR-alpha, DRUG ADMINISTRATION SCHEDULE, TREATMENT OUTCOME, ARTHRITIS",

author = "Otten, {Marieke H.} and Prince, {Femke H. M.} and Marinka Twilt and {van Rossum}, {Marion A. J.} and Wineke Armbrust and Hoppenreijs, {Esther P. A. H.} and Sylvia Kamphuis and Yvonne Koopman-Keemink and Wulffraat, {Nico M.} and Gorter, {Simone L.} and {ten Cate}, Rebecca and {van Suijlekom-Smit}, {Lisette W. A.}",

year = "2010",

month = mar,

doi = "10.3899/jrheum.090550",

language = "English",

volume = "37",

pages = "665--667",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology Publishing Co. Ltd.",

number = "3",

}

Otten, MH, Prince, FHM, Twilt, M, van Rossum, MAJ, Armbrust, W, Hoppenreijs, EPAH, Kamphuis, S, Koopman-Keemink, Y, Wulffraat, NM, Gorter, SL, ten Cate, R & van Suijlekom-Smit, LWA 2010, 'Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept', Journal of Rheumatology, vol. 37, no. 3, pp. 665-667. https://doi.org/10.3899/jrheum.090550

TY - JOUR

T1 - Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept

AU - Otten, Marieke H.

AU - Prince, Femke H. M.

AU - Twilt, Marinka

AU - van Rossum, Marion A. J.

AU - Armbrust, Wineke

AU - Hoppenreijs, Esther P. A. H.

AU - Kamphuis, Sylvia

AU - Koopman-Keemink, Yvonne

AU - Wulffraat, Nico M.

AU - Gorter, Simone L.

AU - ten Cate, Rebecca

AU - van Suijlekom-Smit, Lisette W. A.

PY - 2010/3

Y1 - 2010/3

N2 - Objective. To evaluate response in patients with juvenile idiopathic arthritis (JIA) who failed to meet response criteria after 3 months of etanercept treatment. Methods. This was a prospective ongoing Multicenter observational study of all Dutch patients with JIA using etanercept. Response according to American College of Rheumatology Pediatric 30 criteria was assessed at study start and at 3 and 15 months. Results. In total we studied 179 patients of median age 5.8 years at disease onset; 70% were female. Thirty-four patients did not respond after 3 months, of which 20 continued etanercept and 11 achieved response thereafter. Conclusion. The delayed clinically relevant response in a substantial proportion of patients who initially did not respond justifies the consideration of continuing therapy to at least 6 months. (First Release Jan 15 2010; J Rheumatol 20 10;37:665-7 doi: 10.3899/jrheum.090550)

AB - Objective. To evaluate response in patients with juvenile idiopathic arthritis (JIA) who failed to meet response criteria after 3 months of etanercept treatment. Methods. This was a prospective ongoing Multicenter observational study of all Dutch patients with JIA using etanercept. Response according to American College of Rheumatology Pediatric 30 criteria was assessed at study start and at 3 and 15 months. Results. In total we studied 179 patients of median age 5.8 years at disease onset; 70% were female. Thirty-four patients did not respond after 3 months, of which 20 continued etanercept and 11 achieved response thereafter. Conclusion. The delayed clinically relevant response in a substantial proportion of patients who initially did not respond justifies the consideration of continuing therapy to at least 6 months. (First Release Jan 15 2010; J Rheumatol 20 10;37:665-7 doi: 10.3899/jrheum.090550)

KW - JUVENILE IDIOPATHIC ARTHRITIS

KW - ANTIRHEUMATIC AGENTS

KW - TUMOR NECROSIS FACTOR-alpha

KW - DRUG ADMINISTRATION SCHEDULE

KW - TREATMENT OUTCOME

KW - ARTHRITIS

U2 - 10.3899/jrheum.090550

DO - 10.3899/jrheum.090550

M3 - Article

C2 - 20080910

SN - 0315-162X

VL - 37

SP - 665

EP - 667

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 3

ER -

Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept

Abstract

Keywords

Access to Document

Fingerprint

Cite this